Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D0R1JV
|
|||
| Former ID |
DAP000079
|
|||
| Drug Name |
Ziprasidone
|
|||
| Synonyms |
146939-27-7; Geodon; Zeldox; Ziprasidone hydrochloride; Ziprasidone [INN:BAN]; UNII-6UKA5VEJ6X; CP 88059; Ziprasidone mesylate trihydrate; 6UKA5VEJ6X; CHEMBL708; C21H21ClN4OS; CHEBI:10119; CP-88,059-1; ziprazidone; DSSTox_CID_3753; DSSTox_RID_77186; 5-[2-[4-(1,2-benzothiazol-3-yl)piperazin-1-yl]ethyl]-6-chloro-1,3-dihydroindol-2-one; DSSTox_GSID_23753; ziprasidonum; ziprasidona; 5-(2-(4-(benzo[d]isothiazol-3-yl)piperazin-1-yl)ethyl)-6-chloroindolin-2-one; Geodon; Zipradon; Ziprasidona; Ziprasidonum; Ziprazidone; CP 88059-01; Geodon (TN); Zeldox (TN); Zipradon (TN); Ziprasidone (INN); CP-88,059; CP-88059-1; CP-88,059-01; 5-{2-[4-(1,2-benzisothiazol-3-yl)piperazin-1-yl]ethyl}-6-chloro-1,3-dihydro-2H-indol-2-one; 5-{2-[4-(1,2-benzothiazol-3-yl)piperazin-1-yl]ethyl}-6-chloro-1,3-dihydro-2H-indol-2-one; 6-chloro-5-[2-[4-(7-thia-8-azabicyclo[430]nona-1,3,5,8-tetraen-9-yl)piperazin-1-yl]ethyl]-1,3-dihydroindol-2-one; TC-5280
Click to Show/Hide
|
|||
| Drug Type |
Small molecular drug
|
|||
| Indication | Schizophrenia [ICD-11: 6A20] | Approved | [1], [2], [3] | |
| Therapeutic Class |
Antipsychotic Agents
|
|||
| Company |
Pfizer
|
|||
| Structure |
 |
Download2D MOL |
||
| Formula |
C21H21ClN4OS
|
|||
| Canonical SMILES |
C1CN(CCN1CCC2=C(C=C3C(=C2)CC(=O)N3)Cl)C4=NSC5=CC=CC=C54
|
|||
| InChI |
1S/C21H21ClN4OS/c22-17-13-18-15(12-20(27)23-18)11-14(17)5-6-25-7-9-26(10-8-25)21-16-3-1-2-4-19(16)28-24-21/h1-4,11,13H,5-10,12H2,(H,23,27)
|
|||
| InChIKey |
MVWVFYHBGMAFLY-UHFFFAOYSA-N
|
|||
| CAS Number |
CAS 146939-27-7
|
|||
| PubChem Compound ID | ||||
| PubChem Substance ID |
9771, 7481431, 7980909, 8187099, 14782044, 26719835, 43118192, 46386625, 46507627, 48416712, 49830895, 49984774, 56352942, 57314152, 80112580, 81065539, 85175463, 85209383, 93166200, 96025370, 103194712, 103979184, 104321820, 119525882, 125341301, 126496584, 126618135, 126648879, 126671672, 127275844, 127275845, 127275846, 127275847, 127275848, 127275849, 127275850, 127275851, 127275852, 128655450, 131299396, 134337407, 134338706, 135026475, 135651359, 137001426, 142394815, 144205747, 144207074, 144224623, 152039802
|
|||
| ChEBI ID |
CHEBI:10119
|
|||
| ADReCS Drug ID | BADD_D02389 ; BADD_D02390 ; BADD_D02391 ; BADD_D02415 | |||
| SuperDrug ATC ID |
N05AE04
|
|||
| SuperDrug CAS ID |
cas=146939277
|
|||
| Interaction between the Drug and Microbe | Top | |||
|---|---|---|---|---|
| The Metabolism of Drug Affected by Studied Microbe(s) | ||||
| The Order in the Taxonomic Hierarchy of the following Microbe(s): Bacteroidales | ||||
|
Studied Microbe: Alistipes indistinctus DSM22520
Show/Hide Hierarchy
|
[4] | |||
| Hierarchy | ||||
| Experimental Method | High-throughput screening | |||
| Description | Ziprasidone mesylate can be metabolized by Alistipes indistinctus DSM22520 (log2FC = -0.689; p = 0.022). | |||
|
Studied Microbe: Bacteroides vulgatus ATCC 8482
Show/Hide Hierarchy
|
[4] | |||
| Hierarchy | ||||
| Experimental Method | High-throughput screening | |||
| Description | Ziprasidone mesylate can be metabolized by Bacteroides vulgatus ATCC 8482 (log2FC = -0.632; p = 0.009). | |||
| The Order in the Taxonomic Hierarchy of the following Microbe(s): Enterobacterales | ||||
|
Studied Microbe: Escherichia coli BW25113
Show/Hide Hierarchy
|
[4] | |||
| Hierarchy | ||||
| Experimental Method | High-throughput screening | |||
| Description | Ziprasidone mesylate can be metabolized by Escherichia coli BW25113 (log2FC = -0.54; p = 0.029). | |||
| The Abundace of Studied Microbe(s) Regulated by Drug | ||||
| The Order in the Taxonomic Hierarchy of the following Microbe(s): Eubacteriales | ||||
|
Studied Microbe: Coprococcus comes
Show/Hide Hierarchy
|
[5] | |||
| Hierarchy | ||||
| Abundance Change | Decrease | |||
| Experiment Method | High-throughput screening | |||
| Description | The abundance of Coprococcus comes was decreased by Ziprasidone Hydrochloride (adjusted p-values: 3.65E-03). | |||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | The pipeline and future of drug development in schizophrenia. Mol Psychiatry. 2007 Oct;12(10):904-22. | |||
| REF 2 | URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 59). | |||
| REF 3 | Emerging anxiolytics. Expert Opin Emerg Drugs. 2007 Nov;12(4):541-54. | |||
| REF 4 | Mapping human microbiome drug metabolism by gut bacteria and their genes. Nature. 2019 Jun;570(7762):462-467. | |||
| REF 5 | Extensive impact of non-antibiotic drugs on human gut bacteria. Nature. 2018 Mar 29;555(7698):623-628. | |||
| REF 6 | Striatal and extrastriatal D2/D3-receptor-binding properties of ziprasidone: a positron emission tomography study with [18F]Fallypride and [11C]raclopride (D2/D3-receptor occupancy of ziprasidone). JClin Psychopharmacol. 2008 Dec;28(6):608-17. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.